Xia-Ying Kuang

Here, we sought to provide a landscape of non-synonymous somatic mutations of PI3K pathway in Chinese breast cancer patients. Our cohort included 149 patients ranging from 25 to 72 years of age who were pathologically confirmed at Fudan University Shanghai Cancer Center (FUSCC). The patients’ clinicopathological parameters are listed in Supplementary Table 1. In all, 32 (21.5%) of the patients were Luminal A, 75 (50.3%) were Luminal B, 17 (11.4%) were HER2-enriched, and 25 (16.8%) were TNBC (Fig.

Breast cancer is one of the leading causes of cancer death among women. Although Exciting progress has been made with the chemotherapy of breast cancer, the development of chemoresistance remains a major obstacle to successful treatment of breast cancer [1]. A better understanding of the mechanism of chemoresistance in breast cancer is needed to offer more effective treatment and improve prognosis.